What is the 13F Pro Quality Score for ABUS?

13F Pro ranks Arbutus Biopharma Corp (ABUS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABUS's current score at https://13fpro.ai/research/ABUS (free sign-up required for the full ranking).

Which hedge funds own the most ABUS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ABUS include MORGAN STANLEY, Two Seas Capital, Whitefort Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ABUS as soon as new 13F filings post.

Where does 13F Pro source ABUS data?

All Arbutus Biopharma Corp fundamentals and ownership data come directly from SEC EDGAR. Arbutus Biopharma Corp files with the SEC under CIK 1447028. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABUS in?

Arbutus Biopharma Corp (ABUS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABUS research updated on 13F Pro?

ABUS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arbutus Biopharma Corp(ABUS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1447028 ABUS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ABUS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Arbutus Biopharma Corp (ABUS), a Healthcare sector company. ABUS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Arbutus Biopharma Corp reports quarterly revenue of $179.1M, net income of $169.7M, an operating margin of 94.3%. Top institutional holders of ABUS by reported 13-F value include MORGAN STANLEY, Two Seas Capital, Whitefort Capital Management,, based on the most recent SEC filings. ABUS trades on the Nasdaq exchange and files with the SEC under CIK 1447028. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arbutus Biopharma Corp directly from SEC EDGAR. Arbutus Biopharma Corp's 13F Pro composite quality score has ranged between 3 and 29 since 2021, currently 7.5 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

Revenue

Q1 2026

$179.1M

Net Income

Q1 2026

$169.7M

Free Cash Flow

Q1 2026

$-8.1M

Operating Margin

Q1 2026

94.3%

D/E Ratio

Q1 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-22.4% YoY

$14.1MFY 2025

FY19 $6.0MFY22 $39.0MFY23 $18.1MFY25 $14.1M

Net Income

+54.0% YoY

$-33.5MFY 2025

FY19 $-153.7MFY22 $-69.5MFY23 $-72.8MFY25 $-33.5M

Operating Income

+51.1% YoY

$-38.2MFY 2025

FY19 $-143.9MFY22 $-65.5MFY23 $-78.1MFY25 $-38.2M

EPS (Diluted)

+61.4% YoY

$-0.17FY 2025

FY19 —FY22 $-0.46FY23 $-0.44FY25 $-0.17

Total Assets

-34.5% YoY

$94.6MFY 2025

FY19 $105.5MFY22 $195.4MFY23 $144.4MFY25 $94.6M

Total Debt

$0.00FY 2025

FY19 —FY22 $0.00FY23 $0.00FY25 $0.00

Op. Cash Flow

+53.9% YoY

$-39.6MFY 2025

FY19 $-71.0MFY22 $-35.4MFY23 $-85.9MFY25 $-39.6M

Metric	FY 2025	FY 2023	FY 2022	FY 2019	FY 2018	FY 2017
Revenue	$14.1M -22.4%	$18.1M -53.5%	$39.0M +549.1%	$6.0M +1.1%	$5.9M -44.4%	$10.7M
Net Income	$-33.5M +54.0%	$-72.8M -4.9%	$-69.5M +54.8%	$-153.7M -169.4%	$-57.1M +32.4%	$-84.4M
Operating Income	$-38.2M +51.1%	$-78.1M -19.3%	$-65.5M +54.5%	$-143.9M -60.3%	$-89.8M +19.1%	$-110.9M
EPS (Diluted)	$-0.17 +61.4%	$-0.44 +4.3%	$-0.46	—	$-1.21 +22.4%	$-1.56
Total Assets	$94.6M -34.5%	$144.4M -26.1%	$195.4M +85.2%	$105.5M -53.7%	$227.9M -3.9%	$237.2M
Total Debt	$0.00	$0.00	$0.00	—	—	—
Operating Cash Flow	$-39.6M +53.9%	$-85.9M -143.1%	$-35.4M +50.2%	$-71.0M -4.6%	$-67.9M -39.5%	$-48.6M

AI Insight: ABUS Financial Trends

Q1 2026 revenue surged 1,700% to $179M, driving profitability of $170M net income after eight quarters of losses.

• Revenue exploded from $1M in Q4 2025 to $179M in Q1 2026; net income swung to $170M profit.

• Operating income turned positive at $169M in Q1 2026 after nine consecutive quarters of operating losses.

• Equity surged 238% from $79M in Q1 2025 to $260M in Q1 2026; zero debt throughout.

⚠ Operating cash flow remains negative at $-8M in Q1 2026 despite $170M net income; quality of earnings concern.

⚠ Revenue volatility extreme: Q2 2025 spike to $11M followed by collapse to $1M; sustainability unclear.

AI Insight: ABUS Ratio Trends

Arbutus swung from sustained losses through 2024–early 2025 to near-94% operating margins in Q1 2026, but profitability remains volatile quarter-to-quarter.

• Operating margin jumped to 94.3% in Q1 2026 from 13.9% in Q2 2025; net profit margin similarly surged to 94.7% from 23.5%.

• TTM operating margin of 81.7% and NPM of 84.0% reflect strong recent performance, but Q3 and Q4 2025 both posted negative ROA and ROIC.

• Debt-to-equity ratio remains 0.00 throughout the period; no leverage risk.

⚠ Q3 and Q4 2025 returned to losses (ROA −31.7%, −15.9%) after Q2 2025 profitability; Q1 2026 rebound needs confirmation to rule out seasonality.

⚠ Company transitioned from deep losses in 2024 and Q1 2025 (ROE −123.9%) to positive returns; sustainability of turnaround unproven.

Get alerted when ABUS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arbutus Biopharma Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABUS

MORGAN STANLEY
$116.5M25,891,480 sh
Two Seas Capital LP
$83.5M18,557,543 sh
Whitefort Capital Management, LP
$67.2M14,930,885 sh
BlackRock, Inc.
$58.4M12,966,946 sh
VANGUARD CAPITAL MANAGEMENT LLC
$30.1M6,688,911 sh
Rubric Capital Management LP
$29.8M6,626,389 sh
STATE STREET CORP
$28.5M6,342,510 sh
BARCLAYS PLC
$19.4M4,316,095 sh
GEODE CAPITAL MANAGEMENT, LLC
$17.0M3,771,806 sh
ADAR1 Capital Management, LLC
$14.1M3,133,175 sh

Fund	Value	Shares
MORGAN STANLEY	$116.5M	25,891,480
Two Seas Capital LP	$83.5M	18,557,543
Whitefort Capital Management, LP	$67.2M	14,930,885
BlackRock, Inc.	$58.4M	12,966,946
VANGUARD CAPITAL MANAGEMENT LLC	$30.1M	6,688,911
Rubric Capital Management LP	$29.8M	6,626,389
STATE STREET CORP	$28.5M	6,342,510
BARCLAYS PLC	$19.4M	4,316,095
GEODE CAPITAL MANAGEMENT, LLC	$17.0M	3,771,806
ADAR1 Capital Management, LLC	$14.1M	3,133,175

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ABUS on your watchlist

Track score changes the day Arbutus Biopharma Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABUS a good stock to buy?

13F Pro's AI-powered analysis of Arbutus Biopharma Corp (ABUS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABUS are available on the ABUS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABUS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABUS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arbutus Biopharma Corp's investment landscape.